首页> 外文期刊>Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society >Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis c infection : an observational multicenter study.
【24h】

Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis c infection : an observational multicenter study.

机译:肝移植后新发糖尿病的危险因素和丙型肝炎感染的影响:一项观察性多中心研究。

获取原文
获取原文并翻译 | 示例
           

摘要

New-onset diabetes mellitus (NODM) remains a common complication of liver transplantation (LT). We studied incidence and risk factors in 211 French patients who had undergone a primary LT between 6 and 24 months previously. This is a cross-sectional and retrospective multicenter study. Data were collected on consecutive patients at a single routine post-LT consultation. Demographic details, immunosuppressive regimens, familial and personal histories, hepatitis status, and cardiovascular risk were analyzed to compare those who developed NODM (American Diabetes Association/World Health Organization criteria) with the others. The overall incidence of NODM was 22.7%: 24% in tacrolimus (Tac)-treated patients (n = 175; 82.9%) and 16.7% in cyclosporine-treated patients (n = 36; 17.1%). A total of 81% of the cases were diagnosed within 3 months of LT (M3). Among hepatitis C virus (HCV)-infected (HCV(+)) patients, NODM incidence was 41.7% whereas among those patients negative for this virus (HCV(-)), the incidence was only 18.9% (P = 0.008). In Tac-treated patients, the incidence of NODM in the HCV(+) patients was significantly higher than in the HCV(-) patients (46.7% and 19.3%, respectively, P = 0.0014). Only 1 of 6 (16.7%) of the HCV(+) patients developed NODM on cyclosporine. Other independent pretransplantation risk factors for NODM included impaired fasting glucose (IFG) and a maximum lifetime body-mass index (BMI) over 25 kg/m2. In conclusion, emergence of NODM after LT is related to risk factors that can be detected prior to the graft, like maximum lifetime BMI, IFG, and HCV status. Tac induced a significantly higher incidence of NODM in the HCV(+) compared to the HCV(-) patients. The treatment should therefore be tailored to the patient's risk especially in case of HCV infection.
机译:新发糖尿病(NODM)仍然是肝移植(LT)的常见并发症。我们研究了211名在6至24个月之间接受原发性LT的法国患者的发病率和危险因素。这是一项横断面回顾性多中心研究。在LT后的一次例行咨询中收集连续患者的数据。分析了人口统计学细节,免疫抑制方案,家族和个人病史,肝炎状况以及心血管风险,以将那些患有NODM(美国糖尿病协会/世界卫生组织标准)的人与其他人进行比较。 NODM的总发生率为22.7%:他克莫司(Tac)治疗的患者为24%(n = 175; 82.9%),环孢霉素治疗的患者为16.7%(n = 36; 17.1%)。在LT(M3)的3个月内,总共诊断出81%的病例。在丙型肝炎病毒(HCV)感染(HCV(+))患者中,NODM发生率为41.7%,而在对此病毒阴性的患者(HCV(-))中,发生率仅为18.9%(P = 0.008)。在接受Tac治疗的患者中,HCV(+)患者中NODM的发生率显着高于HCV(-)患者(分别为46.7%和19.3%,P = 0.0014)。在6例HCV(+)患者中,只有1例(16.7%)在环孢霉素上发生NODM。 NODM的其他独立的移植前危险因素包括空腹血糖(IFG)受损和超过25 kg / m2的最大终生身体质量指数(BMI)。总之,LT后NODM的出现与移植前可以检测到的危险因素有关,例如最大寿命BMI,IFG和HCV状态。与HCV(-)患者相比,Tac在HCV(+)中诱导NODM的发生率明显更高。因此,应根据患者的风险调整治疗方法,尤其是在HCV感染的情况下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号